Search
Passage Bio Inc
PASGAdd to Watchlist
4.550USD
-0.330-6.76%
Market hours （ET）Quotes delayed by 15 min
14.60MMarket Cap
LossP/E TTM
More Details of Passage Bio Inc Company
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Passage Bio Inc Info
Ticker SymbolPASG
Company namePassage Bio Inc
IPO dateFeb 28, 2020
CEOChou (William)
Number of employees60
Security typeOrdinary Share
Fiscal year-endFeb 28
AddressOne Commerce Square
CityPHILADELPHIA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19103
Phone12678660312
Websitehttps://www.passagebio.com/
Ticker SymbolPASG
IPO dateFeb 28, 2020
CEOChou (William)
Company Executives of Passage Bio Inc
Name
Name/Position
Position
Shareholding
Change
Mr. William Chou, M.D.
Mr. William Chou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.72K
+5.95%
Ms. Kathleen Borthwick
Ms. Kathleen Borthwick
Chief Financial Officer
Chief Financial Officer
5.40K
+7.39%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
945.00
--
Mr. Edgar B. (Chip) Cale
Mr. Edgar B. (Chip) Cale
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Mr. Sandip S. Kapadia, CPA
Mr. Sandip S. Kapadia, CPA
Independent Director
Independent Director
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Chairwoman of the Board
Independent Chairwoman of the Board
--
--
Dr. Derrell D. Porter, M.D.
Dr. Derrell D. Porter, M.D.
Independent Director
Independent Director
--
--
Dr. Dolan Sondhi, Ph.D.
Dr. Dolan Sondhi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Thomas Kassberg
Mr. Thomas Kassberg
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. William Chou, M.D.
Mr. William Chou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.72K
+5.95%
Ms. Kathleen Borthwick
Ms. Kathleen Borthwick
Chief Financial Officer
Chief Financial Officer
5.40K
+7.39%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
945.00
--
Mr. Edgar B. (Chip) Cale
Mr. Edgar B. (Chip) Cale
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Mr. Sandip S. Kapadia, CPA
Mr. Sandip S. Kapadia, CPA
Independent Director
Independent Director
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Chairwoman of the Board
Independent Chairwoman of the Board
--
--
FAQs
Who are the top five shareholders of Passage Bio Inc?
The top five shareholders of Passage Bio Inc are: Mr. William Chou, M.D.
How many institutions hold shares of Passage Bio Inc (PASG)?
As of 2026Q1, 94 institutions hold shares of Passage Bio Inc, with a combined market value of approximately 1.82M, accounting for 56.60% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -203071.00.